Why Is SciSparc (SPRC) Stock Down -12% Today?
Key Takeaways
- SPRC shares fell roughly 12% in early trading to about $1.76, extending a 44.9% collapse from the prior session.
- The decline follows a dilutive offer to convert a $2.02 million convertible note into equity at just $1.50 per share.
- Investors are also reacting skeptically to the company's newly announced pivot to "Agentic AI," which disclosed no deals, revenue, or funding plan.
- The fixed $1.50 conversion price is acting as a downward anchor well below the stock's recent trading range.
- The move is company-specific, driven by dilution and strategy uncertainty rather than broad biotech weakness.
- Traders are watching whether the conversion closes and whether the company can deliver concrete AI transactions or partnerships.
Opening Summary
SciSparc Ltd. (SPRC), a Tel Aviv-based clinical-stage pharmaceutical company developing cannabinoid-based therapies through its NeuroThera Labs subsidiary, saw its shares extend a steep sell-off on Thursday. The stock fell about 12% to roughly $1.76, down from a prior-session close of $2.00. The decline is the continuation of a dramatic unwind that began on October 15, when shares plunged 44.9% after the company unveiled both a strategic pivot toward "Agentic AI" technologies and a heavily dilutive plan to convert outstanding debt into equity at a sharply discounted price.
A Strategic Pivot That Offered No Financial Substance
The primary catalyst weighing on sentiment is the company's newly announced strategic shift toward Agentic AI-powered technologies, with an initial focus on cybersecurity and finance applications. While pivots toward artificial intelligence often spark speculative rallies, the market treated this one as a warning sign. The announcement disclosed no acquisition targets, no transaction, no budget, and no revenue source — and the company itself cautioned that there can be "no assurance" the effort will produce any deal, commercial agreement, or revenue.
For a micro-cap company with roughly $679,000 in trailing twelve-month revenue and a market capitalization around $1.16 million, the announcement read more like a repositioning statement than a funded strategy. Investors, already wary after a year in which SPRC shares lost the vast majority of their value, interpreted the vague pivot as a sign of limited near-term catalysts in its core drug pipeline rather than a credible growth engine.
Dilution From a Discounted Note Conversion
Compounding the sell-off, the company disclosed an inducement agreement with noteholder L.I.A. Pure Capital Ltd. to convert approximately $2.02 million of outstanding principal and accrued interest into ordinary shares at a fixed price of $1.50 per share. Because the conversion price sits well below the stock's recent trading range, the transaction represents meaningful dilution for existing shareholders — potentially adding well over a million new shares against a float of roughly 561,000 shares.
The $1.50 conversion level is now functioning as a psychological and technical anchor, pulling the share price lower as holders anticipate the influx of newly issued, freely resalable stock. The conversion was expected to close on or about October 16, keeping selling pressure front and center in today's session.
Market Context and Trading Activity
The stock's move is distinctly company-specific rather than a reflection of broader market or biotech-sector weakness. Trading volume has been exceptionally elevated, with more than 34 million shares changing hands in the prior session — many multiples of the stock's typical activity — indicating heavy distribution as investors reassess the company's direction and capital structure.
The decline has also pushed the stock deeper into oversold territory, with technical indicators such as the Relative Strength Index sitting near 19. The shares remain far below their 50-day and 200-day moving averages, and the recent slide has brought the price near the lower end of its 52-week range. The company's long history of reverse stock splits — most recently a 1-for-9 split in March 2026 — has further eroded investor confidence and amplified concerns about ongoing share-count management.
What Comes Next for SPRC
The immediate focus for traders is the completion of the note conversion and whether the resulting dilution is absorbed or triggers further downside. Beyond that, investors will be watching whether the company translates its Agentic AI positioning into any concrete transaction, partnership, or funding arrangement — and whether it can preserve enough capital to advance its core clinical programs, including SCI-110 for Tourette syndrome and SCI-210 for autism spectrum disorder.
The company's next estimated earnings report is slated for around November 20, 2026, which should provide updated visibility into its cash position and burn rate. Key risks include additional dilutive financings, the possibility that the AI pivot fails to materialize into revenue, and the broader challenge of sustaining a micro-cap listing amid persistent losses.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots designed to navigate fast-moving, event-driven markets like the one driving SPRC today. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing traders to find approaches that match their goals. Explore the Trending AI Robots page to discover which strategies are leading the market right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for SPRC turns negative, indicating new downward trend
SPRC saw its Momentum Indicator move below the 0 level on October 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 83 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for SPRC turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 45 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SPRC entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +17.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRC advanced for three days, in 150 of 179 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
SPRC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.673) is normal, around the industry mean (26.782). P/E Ratio (0.051) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.682) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement